Search results
Chinese hamster ovary (CHO) cells are a family of immortalized cell lines derived from epithelial cells of the ovary of the Chinese hamster, often used in biological and medical research and commercially in the production of recombinant therapeutic proteins.
Aug 30, 2022 · Key points. • PI3K/AKT, MAPK, JAK-STAT, and RAP1 pathway receptors are enriched on the CHO cell surface and downstream pathways present on mRNA level. • Detected pathways indicate strong CHO survival and growth phenotypes. • Potential self-induction of surface receptors and respective ligands.
CHO cells are the most widely used cell line for recombinant protein manufacturing, but other cell lines such as those derived from baby hamster kidney (BHK-21), human embryonic kidney (HEK293), and mouse myeloma (NS0 and SP2/0) have also been employed.
The mammalian eukaryotic cells culture approaches, particularly the CHO (Chinese Hamster Ovary) cells are mainly used in the biopharmaceutical industry for the mass-production of the therapeutic protein.
Jan 27, 2023 · Improving the cellular capacity of Chinese hamster ovary (CHO) cells to produce large amounts of therapeutic proteins remains a major challenge for the biopharmaceutical industry.
Jul 21, 2013 · Chinese hamster ovary (CHO) cells, first isolated in 1957, are the preferred production host for many therapeutic proteins.
Chinese hamster ovary (CHO) cells represent the most frequently applied host cell system for industrial manufacturing of recombinant protein therapeutics. CHO cells are capable of producing high quality biologics exhibiting human-like post-translational modifications in gram quantities.
In particular, Chinese hamster ovary (CHO) cells are the most dependable host cells for the industrial production of therapeutic proteins. Growing demand for therapeutic proteins promotes the development of technologies for high quality and productivity in CHO expression systems.
Nov 12, 2019 · The Chinese hamster ovary (CHO) cells used to produce biopharmaceutical proteins are known to contain type‐C endogenous retrovirus (ERV) sequences in their genome and to release retroviral‐like particles. Although evidence for their infectivity is missing, this has raised safety concerns.
Feb 16, 2024 · From Efficiency to Yield: Exploring Recent Advances in CHO Cell Line Development for Monoclonal Antibodies. Review Paper. Published: 16 February 2024. ( 2024 ) Cite this article. Download PDF. Molecular Biotechnology Aims and scope Submit manuscript. Sarmishta Majumdar. Ranjeet Desai. Aakarsh Hans. Prajakta Dandekar. Ratnesh Jain. Accesses.
